FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $42,527,968 | -83.7% | 4,214,863 | -63.8% | 0.37% | -79.7% |
Q3 2022 | $261,207,000 | -1.4% | 11,655,833 | +1.6% | 1.82% | +16.2% |
Q2 2022 | $265,041,000 | -37.8% | 11,473,655 | +4.4% | 1.57% | -11.9% |
Q1 2022 | $426,012,000 | -29.4% | 10,988,182 | +6.6% | 1.78% | -2.5% |
Q4 2021 | $603,365,000 | -6.6% | 10,312,167 | -5.4% | 1.82% | +17.5% |
Q3 2021 | $646,177,000 | -0.5% | 10,902,258 | +45.7% | 1.55% | +28.4% |
Q2 2021 | $649,458,000 | +20.2% | 7,483,102 | +14.2% | 1.21% | +12.7% |
Q1 2021 | $540,422,000 | +104.8% | 6,554,546 | +125.9% | 1.07% | +52.8% |
Q4 2020 | $263,852,000 | +358.4% | 2,901,700 | +101.5% | 0.70% | +105.9% |
Q3 2020 | $57,556,000 | +64.5% | 1,439,970 | +41.2% | 0.34% | -9.3% |
Q2 2020 | $34,990,000 | +183.8% | 1,019,830 | +83.7% | 0.38% | +22.5% |
Q1 2020 | $12,328,000 | +46.1% | 555,082 | +28.8% | 0.31% | +44.1% |
Q4 2019 | $8,437,000 | +60.2% | 431,128 | +27.2% | 0.21% | +85.2% |
Q3 2019 | $5,265,000 | +16.8% | 339,039 | +52.7% | 0.12% | +0.9% |
Q2 2019 | $4,508,000 | – | 222,064 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |